Jefferies Group Boosts Neurocrine Biosciences (NBIX) Price Target to $105.00
Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Jefferies Group to $105.00 in a research note issued to investors on Friday morning, The Fly reports. Jefferies Group currently has a buy rating on the stock. Jefferies Group also issued estimates for Neurocrine Biosciences’ Q1 2018 earnings at ($0.26) EPS, Q2 2018 earnings at $0.25 EPS, Q3 2018 earnings at ($0.13) EPS, Q4 2018 earnings at ($0.13) EPS and FY2022 earnings at $8.08 EPS.
NBIX has been the topic of several other reports. Robert W. Baird reissued a buy rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 3rd. Piper Jaffray Companies reissued a buy rating and issued a $76.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Deutsche Bank reissued a buy rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BMO Capital Markets reissued an outperform rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Finally, Oppenheimer raised their target price on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an outperform rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $81.13.
Neurocrine Biosciences (NASDAQ NBIX) traded up $1.45 on Friday, hitting $81.73. 895,300 shares of the company traded hands, compared to its average volume of 1,149,450. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences has a twelve month low of $38.43 and a twelve month high of $83.57. The firm has a market capitalization of $7,232.54, a PE ratio of -36.82 and a beta of 0.35.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same period in the prior year, the business posted ($0.43) earnings per share. research analysts expect that Neurocrine Biosciences will post -1.66 earnings per share for the current year.
In other news, insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the insider now owns 77,691 shares in the company, valued at $5,794,194.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kyle Gano sold 24,818 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the sale, the insider now owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders have sold 116,405 shares of company stock worth $8,588,519 in the last quarter. Insiders own 4.80% of the company’s stock.
Several large investors have recently modified their holdings of NBIX. Janus Henderson Group PLC bought a new stake in shares of Neurocrine Biosciences in the second quarter worth $246,888,000. HealthCor Management L.P. increased its stake in shares of Neurocrine Biosciences by 108.2% in the second quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock worth $117,308,000 after buying an additional 1,325,178 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after buying an additional 1,214,000 shares during the last quarter. FMR LLC increased its stake in shares of Neurocrine Biosciences by 9.8% in the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after buying an additional 1,180,874 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Neurocrine Biosciences by 53.3% in the second quarter. Goldman Sachs Group Inc. now owns 2,674,217 shares of the company’s stock worth $123,014,000 after buying an additional 930,268 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “Jefferies Group Boosts Neurocrine Biosciences (NBIX) Price Target to $105.00” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/jefferies-group-boosts-neurocrine-biosciences-nbix-price-target-to-105-00/1798773.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.